<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004266</url>
  </required_header>
  <id_info>
    <org_study_id>199/11643</org_study_id>
    <secondary_id>UMN-1967</secondary_id>
    <secondary_id>R01DK047112</secondary_id>
    <nct_id>NCT00004266</nct_id>
  </id_info>
  <brief_title>Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes</brief_title>
  <official_title>Randomized Study of Antihypertensives and Antilipemics in American Indians With Non-Insulin-Dependent Diabetes Mellitus at High Risk of Developing Nephropathy and Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hennepin County Medical Center, Minneapolis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      I. Establish a long-term working relationship between clinical investigators and the
      Minnesota American Indian community.

      II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and
      nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in
      Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria.

      III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A
      reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol
      Education Program in preventing nephropathy and vascular diseases in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:

      Patients are randomly assigned to 1 of 4 treatment groups; therapy continues for 3 years. All
      patients receive instruction on diet, exercise, and smoking cessation.

      The first group receives daily nifedipine at a dose adjusted for high blood pressure.
      Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program
      guidelines. Diuretics and doxazosin may be given concurrently.

      The second group receives daily lisinopril at a dose adjusted for high blood pressure.
      Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program
      guidelines. Diuretics and doxazosin may be given concurrently.

      The third group receives daily nifedipine at a dose adjusted for high blood pressure, and
      simvastatin at a dose adjusted for high low-density lipoproteins. Supplemental cholestyramine
      may be given as needed. If cholestyramine is not tolerated or if triglycerides are high,
      gemfibrozil is substituted for cholestyramine.

      The fourth group receives lisinopril at a dose adjusted for high blood pressure and
      simvastatin at a dose adjusted for high low-density lipoproteins.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1993</start_date>
  <completion_date type="Actual">July 1999</completion_date>
  <primary_completion_date type="Actual">July 1999</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily nifedipine at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lisinopril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily lisinopril at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine and simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily nifedipine at a dose adjusted for high blood pressure, and simvastatin at a dose adjusted for high low-density lipoproteins. Supplemental cholestyramine may be given as needed. If cholestyramine is not tolerated or if triglycerides are high, gemfibrozil is substituted for cholestyramine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lisinopril and simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lisinopril at a dose adjusted for high blood pressure and simvastatin at a dose adjusted for high low-density lipoproteins.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <arm_group_label>Lisinopril</arm_group_label>
    <arm_group_label>Lisinopril and simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_label>Nifedipine and simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <arm_group_label>Nifedipine and simvastatin</arm_group_label>
    <arm_group_label>Lisinopril and simvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Non-insulin-dependent diabetes mellitus with documented fasting
        hyperglycemia Microalbuminuria OR clinically detectable albuminuria; Urine albumin
        excretion rate at least 30 mg/24 hours Low-density lipoproteins (fasting) at least 80 mg/dL
        Recruitment from American Indian population at Red Lake and Leech Lake reservations

        --Prior/Concurrent Therapy-- At least 5 days since antihypertensives or antilipemics

        --Patient Characteristics-- Renal: Urine albumin-to-creatinine ratio at least 30 mg/g;
        Creatinine clearance or estimated creatinine clearance at least 30 mL/min; No active urine
        sediment suggestive of glomerulonephritis, i.e.: No RBCs greater than 10/high-power field;
        No WBCs greater than 15/high-power field; No RBC casts

        Cardiovascular: No symptomatic orthostatic hypotension; No poorly-compensated congestive
        heart failure; No requirement for angiotensin-converting enzyme inhibitors; No angina
        pectoris requiring nifedipine; No unstable angina; No episodes of angina occurring more
        than once a month; No chest pain of undetermined cause within 1 month; No severe
        hypertension requiring multiple antihypertensives; No myocardial infarction within 1 year;
        No stroke or transient ischemic attack within 1 year

        Other: No known allergy to nifedipine, lisinopril, or simvastatin; No untreated
        proliferative retinopathy; Documented retinal exam within 1 year prior to entry; No alcohol
        or drug abuse affecting compliance; No other debilitating or acute illness; No pregnant or
        nursing women; Effective contraception required of fertile women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertram L. Kasiske</last_name>
    <role>Study Chair</role>
    <affiliation>Hennepin County Medical Center, Minneapolis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetic nephropathy</keyword>
  <keyword>rare disease</keyword>
  <keyword>renal and genitourinary disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

